drugset / Trial / NCT05430243
Empagliflozin as a Novel Therapy in Refractory Ascites
RandomizedParallel-groupDouble-blindTreatment
Summary
The aim of the present study is to investigate the safety, efficacy and cost-effectiveness of empagliflozin, a sodium glucose transporter 2 inhibitor, as an add on therapy to the standard care for refractory ascites in patients with liver cirrhosis
Timeline
- Start
- 2022-04-21
- Primary completion
- 2022-11-12
- Completion
- 2022-11-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Empagliflozin | Small molecule | 10 mg | — |
Indications
No indication recorded.